Tectonic Therapeutic (TECX) director receives 10,200 stock options at $28.56

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. director Phillip B. Donenberg reported a compensation-related equity award. He received a stock option to acquire 10,200 shares of common stock at an exercise price of $28.56 per share, giving him the right, but not the obligation, to buy company stock at that price.

The option vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a qualifying change in control, as long as he continues serving the company through that date. Following this grant, he holds 10,200 stock options directly, with an expiration date in 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Donenberg Phillip B.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,200 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 10,200 options Exercise price: $28.56 per share Underlying shares: 10,200 shares +3 more

6 metrics

Option grant size 10,200 options Stock Option (Right to Buy) granted to director

Exercise price $28.56 per share Stock option strike price

Underlying shares 10,200 shares Common Stock underlying the option

Expiration date June 8, 2036 Option term end date

Post-grant derivative holdings 10,200 options Total options held after transaction

Vesting latest date June 9, 2027 Latest scheduled vesting condition

Key Terms

Stock Option (Right to Buy), Common Stock, Equity Incentive Plan, Change in Control, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Common Stock financial

"underlying_security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Equity Incentive Plan financial

"as defined in the Issuer's 2024 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Change in Control financial

"or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Annual Meeting of Stockholders financial

"the date of the Issuer's 2027 Annual Meeting of Stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donenberg Phillip B.

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$28.56	06/09/2026		A		10,200		(1)	06/08/2036	Common Stock	10,200	$0	10,200	D

Explanation of Responses:

1. The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

	/s/ Daniel Lochner, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TECX director Phillip B. Donenberg report?

Phillip B. Donenberg reported receiving a stock option grant for 10,200 shares of Tectonic Therapeutic common stock. The option is a compensation award, not an open-market trade, and gives him the right to buy shares at a fixed exercise price of $28.56.

What are the key terms of Phillip Donenberg’s TECX stock option grant?

The grant covers 10,200 underlying common shares at a $28.56 exercise price and expires on June 8, 2036. It vests in full on the earliest of June 9, 2027, the 2027 annual meeting, or a qualifying change in control, subject to continued service.

Does the Form 4 for TECX show any stock being bought or sold?

The Form 4 shows no open-market buying or selling of Tectonic Therapeutic shares. It reports a single compensation-related stock option grant coded as an acquisition (A), with no corresponding sale or exercise transactions disclosed in this filing.

How many TECX derivative securities does Phillip Donenberg hold after this transaction?

After the reported transaction, Phillip Donenberg holds 10,200 stock options relating to Tectonic Therapeutic common stock. These options were granted at a $28.56 exercise price and represent his direct derivative position as reflected in this specific Form 4 filing.

When will Phillip Donenberg’s TECX option award vest?

The option will vest in full at the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a defined change in control. Vesting in each case depends on Donenberg continuing to provide service to Tectonic Therapeutic through the applicable date.